INVIVO THERAPEUTICS HLDGS CO's ticker is NVIV and the CUSIP is 46186M209. A total of 51 filers reported holding INVIVO THERAPEUTICS HLDGS CO in Q2 2017. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2018 | $12,000 | -29.4% | 22,900 | 0.0% | 0.00% | – |
| Q4 2017 | $17,000 | -50.0% | 22,900 | 0.0% | 0.00% | – |
| Q3 2017 | $34,000 | -96.7% | 22,900 | -94.1% | 0.00% | – |
| Q2 2017 | $1,043,000 | -44.5% | 384,976 | -17.0% | 0.00% | – |
| Q1 2017 | $1,878,000 | +2.3% | 463,666 | +6.5% | 0.00% | – |
| Q4 2016 | $1,835,000 | -35.6% | 435,559 | +4.0% | 0.00% | – |
| Q3 2016 | $2,848,000 | +20.0% | 418,751 | +2.0% | 0.00% | – |
| Q2 2016 | $2,373,000 | -15.0% | 410,504 | +2.5% | 0.00% | – |
| Q1 2016 | $2,793,000 | +13.8% | 400,297 | +17.5% | 0.00% | – |
| Q4 2015 | $2,455,000 | -13.6% | 340,562 | +3.2% | 0.00% | – |
| Q3 2015 | $2,842,000 | -35.1% | 329,878 | +21.8% | 0.00% | – |
| Q2 2015 | $4,378,000 | – | 270,920 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| IMS Capital Management | 246,966 | $1,778,000 | 2.19% |
| WELCH & FORBES LLC | 902,286 | $6,496,000 | 0.21% |
| Alambic Investment Management, L.P. | 25,100 | $181,000 | 0.11% |
| EMERSON INVESTMENT MANAGEMENT, LLC | 74,175 | $534,000 | 0.10% |
| Hayek Kallen Investment Management | 10,965 | $79,000 | 0.06% |
| Yellowstone Partners, LLC | 10,045 | $72,000 | 0.03% |
| Ausdal Financial Partners, Inc. | 7,750 | $56,000 | 0.03% |
| LANDSCAPE CAPITAL MANAGEMENT, L.L.C. | 29,647 | $213,000 | 0.03% |
| GROUP ONE TRADING, L.P. | 61,856 | $445,000 | 0.01% |
| Cambridge Investment Research Advisors, Inc. | 10,500 | $76,000 | 0.00% |